FDA: Page
-
Ireland threatens to cap drug prices
The Irish government is considering capping prices on older medications, because drug makers are unwilling to lower prices.
By Nicole Gray • Feb. 3, 2015 -
UPDATE: Obama budget proposes historic, direct Medicare drug price negotiations
It would be a game-changing shift in an era of high-priced specialty drugs. But PhRMA is already hitting back hard—and does the plan even have a chance of passing a Republican Congress?
By Sy Mukherjee • Feb. 2, 2015 -
Shire's Vyvanse nabs FDA approval for binge-eating disorder
ADHD drug Vyvanse is now FDA-approved for treatment of binge-eating disorder (BED), based on strong phase III data showing that it is superior to placebo in terms of curbing BED.
By Nicole Gray • Feb. 2, 2015 -
Deep Dive
What will the new federal budget mean for pharmaceutical R&D tax credits?
The Senate Finance Committee has vowed to reform the tax code. What does it mean for pharma and R&D tax credits?
By Nicole Gray • Feb. 1, 2015 -
J&J's Imbruvica gets expanded label for rare blood cancer treatment
Until recently, there were no treatments for Waldenstroms macroglobulinemia (WM), a rare blood cancer.
By Nicole Gray • Jan. 30, 2015 -
Some UK cystic fibrosis patients being denied breakthough treatment
At $307,000 per year, Vertex's Kalydeco has some UK payers balking.
By Nicole Gray • Jan. 30, 2015 -
J&J under continued scrutiny for off-label pediatric use of Risperdal
After paying a $2.2 billion settlement to the Department of Justice in 2013, J&J is again under fire for failing to warn parents about certain Risperdal side effects, including boys growing breasts.
By Nicole Gray • Jan. 30, 2015 -
Pfizer dodges class-action trial with $400 million settlement
Pfizer has been accused of misleading statements and off-label marketing involving Bextra (valdecoxib) and other drugs.
By Nicole Gray • Jan. 29, 2015 -
Deep Dive
4 things you need to know about the sweeping FDA reform bill Congress just proposed
The 21st Century Cures initiative has bipartisan support. And it could be the biggest U.S. healthcare shakeup since Obamacare, transforming core elements of the regulatory and clinical trials pathway.
By Sy Mukherjee • Jan. 28, 2015 -
Counterfeit Roche cancer drug smuggler gets 30 months in jail
Sabahaddin Akman, owner of Turkey-based Ozay Pharmaceuticals, is going to prison for 30 months for smuggling fake cancer drugs into the U.S.
By Nicole Gray • Jan. 27, 2015 -
Rumor mill churns as Duke's Dr. Robert Califf appointed FDA deputy commish
In his new role at the FDA, Dr. Califf will have a huge amount of responsibility. Could it be in preparation for a future role as the head of the agency?
By Nicole Gray • Jan. 27, 2015 -
Teva wins big as FDA approves its generic Nexium
Generic esomeprazole, used to reduce stomach acid and treat gastroesophageal reflux disease (GERD), is expected to be one of the biggest generic drug launches ever.
By Nicole Gray • Jan. 27, 2015 -
GSK denies reports of imminent job cuts in China
Since its well-publicized bribery scandal in China, GSK has been working hard to boost sales—while also vigorously denying rumors of job cuts.
By Nicole Gray • Jan. 26, 2015 -
Shire pleased as NPS Pharma wins Natpara approval
The FDA's approval of Natpara (recombinant human parathyroid hormone) bodes well as Shire gets close to completing its $5.2 billion acquisition of NPS Pharma,.
By Nicole Gray • Jan. 26, 2015 -
EMA suspending almost 50 drugs over flawed CRO clinical studies
The FDA has yet to take action on the issue, which involves serial data manipulation by an India-based CRO.
By Nicole Gray • Jan. 26, 2015 -
Novartis nabs FDA nod for group B meningitis vaccine Bexsero
Bexsero, which was used on an emergency basis in 2013 in response to a meningitis outbreak at two U.S. universities, is now FDA-approved for regular use.
By Nicole Gray • Jan. 26, 2015 -
Sanofi/Regeneron off to the races with priority review of cholesterol game-changer
Sanofi/Regeneron's BLA for PCSK9 candidate Praluent (alirocumab) has nabbed an FDA priority review based on massive ongoing trials involving more than 23,000 patients.
By Sy Mukherjee • Jan. 26, 2015 -
EU approves Genzyme's Cerdelga for type 1 Gaucher patients
Cerdelga (eliglustat) won U.S. approval last August.
By Nicole Gray • Jan. 23, 2015 -
UPDATED: Sen. Elizabeth Warren proposes big new pharma fines to fund NIH research
The firebrand Massachusetts senator likens her proposed Medical Innovation Act to a "swear jar" for lawbreaking pharma companies with blockbuster drugs.
By Sy Mukherjee • Jan. 22, 2015 -
J&J: Regulatory delays in China are stymying drug approvals
Speaking at the World Economic Forum in Davos, J&J's chief scientific officer said that getting a product approved in China can take as long as seven years. J&J is not alone in facing this problem in China.
By Nicole Gray • Jan. 22, 2015 -
Deep Dive
Chasing transparency in the pharmaceutical industry: How much is enough?
The Cochrane Collaboration has revealed that a large number of negative clinical trial data go unreported. But the combination of technology and advocacy may shift the way data is collected, viewed, and accessed.
By Nicole Gray • Jan. 22, 2015 -
Plaintiffs wanted: Law firms seek shareholders to launch a Sanofi kickback suit
2014 was a hard year for Sanofi, with the forced departure of CEO Viehbacher and a high-profile whistleblower lawsuit involving a former employee. But 2015 could get even worse.
By Nicole Gray • Jan. 22, 2015 -
FDA approves likely Novartis psoriasis blockbuster Cosentyx
Cosentyx is now cleared for the treatment of moderate-to-severe plaque psoriasis in American adults.
By Sy Mukherjee • Jan. 21, 2015 -
Teva wins Copaxone patent protection suit in US Supreme Court
After losing a patent-protection suit related to Copaxone in the U.S. Court of Appeals for the Federal Circuit, Teva took it all the way to the top—and won.
By Nicole Gray • Jan. 21, 2015 -
One more push: Senators reintroduce bill to expedite antibiotic approval
Senators Orrin Hatch (R-UT) and Michael Bennett (C-CO) have reintroduced the Promise for Antibiotics and Therapeutics for Health (PATH) Act.
By Nicole Gray • Jan. 20, 2015